Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

2(33%)

Results Posted

100%(1 trials)

Terminated

2(33%)

Phase Distribution

Ph phase_2

50%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Terminated(2)

Other(1)

Detailed Status

Terminated2

Recruiting2

Completed1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (40.0%)

Phase 23 (60.0%)

Trials by Status

terminated233%

recruiting233%

completed117%

unknown117%

Recent Activity

2 active trials

Showing 5 of 6

recruitingphase_2

Clinical Trials (6)

Showing 6 of 6 trials

NCT06424756Phase 2

Effects of an Antioxidant Supplement on Blood Vessel Health

Recruiting

NCT03480971Phase 2

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Recruiting

NCT04729595Phase 2

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Terminated

NCT05491928

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Unknown

NCT01324141Phase 1

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Terminated

NCT03680638Phase 1

The Effect of Antioxidants on Skin Blood Flow During Local Heating

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6